募集资金存放与实际使用情况鉴证报告 上海谊众药业股份有限公司 容诚专字[2025]200Z0164号 ) 容诚会计师事务所(特殊普通合伙 中国·北京 | | | | 序号 | | 内 | 容 | 页码 | | --- | --- | --- | --- | --- | | 1 | 募集资金存放与实际使用情况鉴证报告 | | | 1-3 | | 2 | 募集资金存放与实际使用情况的专项报告 | | | 1-6 | 募集资金存放与实际使用情况鉴证报告 容诚专字[2025]200Z0164号 上海谊众药业股份有限公司全体股东 ： 我们审核了后附的上海谊众药业股份有限公司（以下简称上海谊众公司）董 事会编制的 2024 年度《募集资金存放与实际使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供上海谊众公司年度报告披露之目的使用，不得用作任何其他 目的。我们同意将本鉴证报告作为上海谊众公司年度报告必备的文件，随其他文 件一起报送并对外披露。 二、 董事会的责任 按照中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、上海证券交易所《上海证券交易所科创板 ...

国金证券股份有限公司 关于上海谊众药业股份有限公司 2024 年度募集资金存放与使用情况的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海谊众药 业股份有限公司（以下简称"上海谊众"或"公司"）首次公开发行股票并在科创板上 市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《科创板上市公司持 续监管办法（试行）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》《上海证券交易所科创板股票上市规则》以及《上海证券交易所上市公司自 律监管指引第 11 号——持续督导》等有关规定，对上海谊众 2024 年度募集资金的存 放和使用情况进行了核查，具体情况如下： 一、首次公开发行股票募集资金的基本情况 （一）实际募集资金金额、资金到账情况 经中国证券监督管理委员会于 2021 年 8 月 3 日发布的《关于同意上海谊众药业股 份有限公司首次公开发行股票注册的批复》（证监许可[2021]2595 号）同意，公司向社 会公众公开发行人民币普通股（A 股）股票 2,645.00 万股，每股面值 1 元，发行价格 为每股人民币 38.10 元，募集资金总额为人民币 10 ...

内部控制审计报告 上海谊众药业股份有限公司 容诚审字[2025]200Z0043号 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了上海谊众药业股份有限公司（以下简称"上海谊众公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 ) 容诚会计师事务所(特殊普通合伙 中国·北京 内部控制审计报告 容诚审字[2025]200Z0043号 上海谊众药业股份有限公司全体股东 ： 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是上海 谊众公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认 ...

国金证券股份有限公司 关于上海谊众药业股份有限公司 2024 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、法规的 规定，国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海谊众药 业股份有限公司（以下简称"上海谊众"、"上市公司"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，负责上海谊众上市后的持续督导工作，并出具本持续督导 跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并针对 | 保荐机构已建立健全并有效执行了 | | 1 | | 持续督导制度，并制定了相应的工作 | | | 具体的持续督导工作制定相应的工作计划 | 计划 | | | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与公司签订《保荐协议》， | | | 前，与上市公司或相关当事人签署持续督导协议， | 该协议明确了双方在持续督导期间的 | | 2 | 明确双方在持续督导期间的权利义务，并报 ...

国金证券股份有限公司 截至 2021 年 9 月 3 日，公司本次募集资金净额 93,603.05 万元已全部到位， 并由容诚会计师事务所（特殊普通合伙）对公司募集资金的到位情况进行了审验， 并出具了容诚验字[2021]201Z0041 号《验资报告》，公司依照规定对上述募集资 金进行专户存储管理，并与保荐机构、募集资金专户监管银行签订了募集资金专 户存储监管协议。 二、募集资金使用计划及使用情况 （一）募集资金使用计划 按照公司《首次公开发行股票并在科创板上市招股说明书》披露的募集资金 投资项目，以及公司根据实际募集资金到账情况对各募投项目募集资金投资金额 1 关于上海谊众药业股份有限公司 部分募投项目延期的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海谊众 药业股份有限公司（以下简称"上海谊众"或"公司"）首次公开发行股票并在科创 板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管规则适 用指引第1号——规范运作》及《科 ...

国金证券股份有限公司 关于上海谊众药业股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监 管指引第11号——持续督导》等有关法律、法规的规定，国金证券股份有限公司（以 下简称"保荐机构"、"国金证券"）作为上海谊众药业股份有限公司（以下简称"上海谊 众"、"上市公司"、"公司"）持续督导保荐机构，对公司2024年度（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 国金证券股份有限公司 （二）保荐代表人 顾兆廷、秦勤 （三）现场检查人员 秦勤 （四）现场检查时间 2024年4月21日 （五）现场检查内容 公司治理及内部控制，信息披露，独立性，募集资金使用情况，公司经营状况， 是否存在与关联方的资金往来、关联交易、对外担保、重大对外投资等情况。 （六）现场检查手段 6、查阅上市公司 2024 年度定期报告、临时报告等信息披露文件； 7、核查上市公司 2024 年度是否发生与关联方的资金往来、关联交易、对外担保、 重大对外投资等情况。 二、现场检查的具体 ...

Financial Performance - The company's operating revenue for 2024 was ¥173,532,721.07, a decrease of 51.83% compared to ¥360,253,871.23 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥6,975,282.60, down 95.68% from ¥161,553,919.38 in 2023[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,891,951.20, a decline of 97.58% from ¥161,065,688.52 in 2023[21]. - The net cash flow from operating activities for 2024 was ¥39,437,023.16, a decrease of 54.44% compared to ¥86,554,073.66 in 2023[21]. - The total assets at the end of 2024 were ¥1,447,992,684.90, down 7.97% from ¥1,573,359,475.20 at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were ¥1,405,020,800.85, a decrease of 4.08% from ¥1,464,836,602.87 at the end of 2023[21]. - Basic and diluted earnings per share dropped to 0.03 yuan per share, a decline of 97.06% from 1.02 yuan per share in 2023[22]. - The weighted average return on equity fell to 0.49%, a decrease of 11.29 percentage points from 11.78% in 2023[22]. Research and Development - The company emphasizes the importance of its R&D efforts in developing new drug formulations and technologies[11]. - Research and development investment as a percentage of operating revenue increased by 6.23 percentage points[23]. - The company has increased R&D investment, focusing on expanding the indications for injectable paclitaxel polymer micelles, with ongoing phase III clinical trials for breast cancer and pancreatic cancer[41]. - The company has developed two new drugs: a multifunctional monoclonal antibody YXC-001 and a small molecule targeted drug YXC-002, both of which are in preclinical research[36]. - R&D expenses rose significantly by 65.71% to ¥37,203,747.41, indicating a strong focus on innovation[149]. - The company has maintained a stable R&D team without any core personnel turnover during the reporting period[109]. - The company is actively expanding clinical trials for its core product, paclitaxel micelles, to increase the number of registered indications[109]. Product Development and Market Strategy - The company’s core product, paclitaxel polymer micelles, continues to be a key focus in its product lineup[11]. - The core product, paclitaxel micelles, was successfully included in the national medical insurance directory, which is expected to enhance market promotion and sales[37]. - The company is preparing for the 2024 medical insurance negotiations for its core product, engaging third-party experts for guidance and research[34]. - The company aims to adapt quickly to external changes while ensuring safe and steady development[30]. - The company is focused on building a strong brand image centered on clinical value, product quality, and technological innovation[184]. - The company is expanding its marketing team and implementing performance assessment and incentive mechanisms to improve overall performance and employee engagement[82]. - The company is leveraging digital marketing strategies to enhance drug accessibility and optimize channel inventory management[82]. Operational Challenges and Risks - The company has not faced any significant risks that could materially impact its operations during the reporting period[4]. - The company experienced significant challenges in marketing its core product due to difficulties in market access and changes in the pharmaceutical industry environment[30]. - The company's future operational plans and development strategies are subject to risks and do not constitute substantive commitments to investors[6]. - The rapid development of new cancer therapies, including targeted and immunotherapies, poses a risk to the company's existing and pipeline products if more effective treatments emerge[133]. - The company must adapt to regulatory changes in the healthcare system, as price declines in drug procurement could negatively impact sales revenue and net profit[134]. Corporate Governance and Management - The company has maintained a standard unqualified audit opinion from its accounting firm, ensuring the accuracy of its financial reports[5]. - The company’s management has committed to ensuring the authenticity and completeness of the annual report[5]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[7]. - The company has held 5 board meetings and 4 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements[189]. - The company is committed to enhancing its internal control systems and governance structure to support high-quality development[186]. Market Trends and Industry Outlook - The global pharmaceutical market is projected to reach $1.5 trillion in 2023, with a CAGR of 3%-6% from 2023 to 2027, driven by innovative drugs related to oncology and immunotherapy[84]. - China's pharmaceutical market is expected to grow from approximately $165 billion in 2022 to $195 billion in 2024, with increasing demand in oncology, diabetes, and chronic disease sectors[86]. - The global oncology drug market was valued at $150.3 billion in 2020 and is expected to grow to $304.8 billion by 2025, reflecting a CAGR of 15.2%[90]. - The company is positioned to benefit from the ongoing reforms in the healthcare system, which are expected to create new growth opportunities in the pharmaceutical industry[158]. Shareholder Information - The total number of shares held by the chairman and general manager, Zhou Jinsong, increased from 33,531,344 to 43,590,747, reflecting a change of 10,059,403 shares due to the implementation of the capital reserve conversion into share capital plan[194]. - The total number of shares held by the company’s board members and senior management increased from 41,129,494 to 53,554,342, a total increase of 12,424,848 shares[196]. - The total pre-tax remuneration for Zhou Jinsong in the reporting period was 150.12 million yuan, with no remuneration received from related parties[194]. - The total pre-tax remuneration for the board members and senior management in the reporting period amounted to 594.67 million yuan[196].

Financial Performance - The company's revenue for Q1 2025 was ¥71,032,214.87, representing a year-on-year increase of 3.39% compared to ¥68,702,991.41 in the same period last year[5] - Net profit attributable to shareholders decreased by 51.38% to ¥14,185,975.54 from ¥29,178,031.68 in the previous year[5] - The basic earnings per share decreased by 61.11% to ¥0.07 from ¥0.18 in the same period last year[5] - Net profit for Q1 2025 was ¥14,185,975.54, a decrease of 51.5% from ¥29,178,031.68 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.07, down from ¥0.18 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was negative at -¥35,461,931.24, a decline of 222.80% compared to ¥28,877,820.51 in the same period last year[5] - Cash flow from operating activities in Q1 2025 was negative at -¥35,461,931.24, compared to a positive cash flow of ¥28,877,820.51 in Q1 2024[22] - Cash inflow from investment activities in Q1 2025 was ¥2,265,244,086.29, significantly higher than ¥327,424,747.27 in Q1 2024[22] - The company reported a net cash outflow from investment activities of -¥13,182,738.71 in Q1 2025, compared to a net inflow of ¥15,609,268.37 in Q1 2024[22] - The net cash flow from financing activities was $2,588,963.52, compared to $8,805,402.79 in the previous period[23] - The net increase in cash and cash equivalents was a decrease of $46,055,706.43, contrasting with an increase of $53,292,491.67 previously[23] - The ending balance of cash and cash equivalents stood at $598,350,982.88, down from $963,178,159.26 at the beginning of the period[23] Research and Development - Research and development expenses totaled ¥9,276,624.21, an increase of 65.78% from ¥5,595,803.86 in the previous year, accounting for 13.06% of revenue[6] - Research and development expenses increased to ¥9,276,624.21 in Q1 2025, compared to ¥5,595,803.86 in Q1 2024, reflecting a growth of 65.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,466,791,387.83, a slight increase of 1.30% from ¥1,447,992,684.90 at the end of the previous year[6] - The total assets of the company are ¥1,466,791,387.83, compared to ¥1,447,992,684.90 at the end of 2024, indicating an increase[15] - The total liabilities as of March 31, 2025, are ¥40,773,311.62, compared to ¥39,446,131.43 at the end of 2024[15] - Total liabilities increased to ¥44,115,058.89 in the latest reporting period, compared to ¥42,971,884.05 previously[16] - The total non-current assets amount to ¥694,171,916.47, an increase from ¥671,785,597.36 at the end of 2024[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,144[10] - The largest shareholder, Zhou Jinsong, holds 40,127,058 shares, representing 19.41% of total shares[10] - The company has a total of 24,703,546 shares held by Shanghai Kaibao Pharmaceutical Co., Ltd., representing 11.95% of total shares[11] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[12] Operational Performance - The company reported a 348% increase in sales volume of its core product, paclitaxel micelles, which was included in the medical insurance list[8] - Total operating revenue for Q1 2025 reached ¥71,032,214.87, an increase of 3.86% compared to ¥68,702,991.41 in Q1 2024[18] - Total operating costs for Q1 2025 were ¥53,585,184.88, up 44.73% from ¥36,997,180.69 in Q1 2024[18] - The company experienced increased costs in raw material procurement, marketing expenses, and R&D investments, impacting overall profitability[8] Equity - Total equity attributable to shareholders rose to ¥1,422,676,328.94 from ¥1,405,020,800.85, indicating a growth of 1.25%[16] Accounting Standards - The company will not apply new accounting standards starting from 2025[23]

上海谊众公告，2024年营业收入1.74亿元，同比减少51.83%。归属于上市公司股东的净利润697.53万 元，同比减少95.68%。基本每股收益0.03元／股，同比减少97.06%。2024年度公司拟定不再实施现金分 红或转增股本等权益分派方案。 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...